SCG Cell Therapy utilizes the patient's immune system to target and eliminate cancerous cells and pathogenic infections. This approach aims to enhance the effectiveness of cancer treatment by harnessing the body's natural defenses.
Funding
$41M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often have limited effectiveness and can cause significant side effects. Harnessing the patient's own immune system to fight cancer offers a more targeted and potentially less toxic approach.
Solution
SCG Cell Therapy develops immunotherapies that utilize a patient's own immune cells to target and eliminate cancerous cells and pathogenic infections. By modifying and enhancing these cells, SCG aims to improve the precision and effectiveness of cancer treatment while minimizing harm to healthy tissues. This approach seeks to overcome the limitations of conventional therapies by leveraging the body's natural defenses to combat disease.
Target Audience
The primary target audience includes patients with various types of cancer and infectious diseases, as well as oncologists and hematologists seeking innovative treatment options.
Features
- Utilizes autologous cell therapy, employing the patient's own immune cells to minimize the risk of rejection.
- Genetically engineers immune cells to enhance their ability to recognize and destroy cancer cells.
- Develops targeted therapies designed to specifically attack cancer cells while sparing healthy tissue.